Vaccination against the human cytomegalovirus
- PMID: 29622379
- PMCID: PMC6892274
- DOI: 10.1016/j.vaccine.2018.02.089
Vaccination against the human cytomegalovirus
Abstract
The human cytomegalovirus (HCMV) is the most important infectious cause of congenital abnormalities and also of infectious complications of transplantation. The biology of the infection is complex and acquired immunity does not always prevent reinfection. Nevertheless, vaccine development is far advanced, with numerous candidate vaccines being tested, both live and inactivated. This article summarizes the status of the candidate vaccines.
Keywords: CMV; Congenital infection; Deafness; Pentamer; Reinfection.
Copyright © 2018. Published by Elsevier Ltd.
References
-
- Camargo J.F., Komanduri K.V. Emerging concepts in cytomegalovirus infection following hematopoietic stem cell transplantation. Hematol Oncol Stem Cell Ther. 2017 - PubMed
-
- Ljungman P., Boeckh M., Hirsch H.H., Josephson F., Lundgren J., Nichols G. Definitions of cytomegalovirus infection and disease in transplant patients for use in clinical trials. Clin Infect Dis. 2017;64(1):87–91. - PubMed
-
- Kenneson A., Cannon M.J. Review and meta-analysis of the epidemiology of congenital cytomegalovirus (CMV) infection. Rev Med Virol. 2007;17(4):253–276. - PubMed
-
- Boppana SB, Britt WJ. Synopsis of clinical aspects of human cytomegalovirus disease. In: Reddehase MJ, editor. Cytomegaloviruses: from molecular pathogenesis to intervention, vol. II. Norfolk, U.K.: Caister Academic Press; 2013. p. 1–25.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
